StockWatch
·

NUCLEUS SOFTWARE EXPORTS LTD.

BSE: 531209

P/L Snapshot

Q2 FY27 · standalone

vs Q1 FY27·vs Q2 FY26
Revenue
224.02
+6.0%+4.0%
Expenditure
200.40
+4.1%+12.1%
Net Profit
19.12
-16.7%-31.3%
OPM %
6.23%
-2.12pp-4.67pp

Shareholding

Pattern breakdown

P/L Trends

(in crores)

RevenueExpenditureNet Profit
0.0064.27128.53192.80257.06Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Price Chart
Reports

Nucleus Software Q2 FY27: consolidated profit slips 19% YoY to ₹21.3 Cr, margins compress

it services · banking software · margin compression

ResultsQ2 FY2731 Oct 20263 minTechnology / IT

Order book surges, but earnings and margins crumble

order book · margin collapse · cost structure

Result verdictFollow-upQ1 FY2703 Aug 20266 minTechnology / IT

Order book surge fails to mask margin collapse; execution risk ahead

order book growth · margin compression · customer loss

TranscriptDeep diveQ1 FY2703 Aug 20266 minTechnology / IT
Latest
Board Meeting31 Oct, 4:10 pm

Nucleus Software Q2 FY27: consolidated profit slips 19% YoY to ₹21.3 Cr, margins compress

Nucleus Software's consolidated revenue grew 6.65% YoY to ₹227.70 Cr (also +8.21% QoQ from ₹210.43 Cr), but PAT fell 19.2% YoY to ₹21.25 Cr and 11.0% QoQ from ₹23.87 Cr — profit declining even as the topline advanced, so the YoY read is a soft print despite growth. No analyst consensus for this specific quarter turned up in a web search, so the result cannot be graded against street expectations (vsStreet: unknown). Management also gave no numeric revenue or margin guidance on the Q1 FY27 call — only qualitative commentary around a growing order book — so there is no formal guidance bar to measure this print against either. Net margin (PAT/total income) compressed to 8.72% from 11.45% a year ago and 10.46% last quarter. Employee costs, the dominant cost line, rose to 72.1% of revenue from 69.1% YoY (₹164.2 Cr vs ₹147.5 Cr) — though they eased from Q1's elevated 74.7% — while operating & other expenses crept up to 20.9% of revenue from 19.9% YoY. The squeeze is purely operating: this quarter carried zero exceptional items, so Q1 FY27's reported ₹30.1 Cr PBT (inflated by the one-off gratuity/leave gain) is not comparable to this quarter's clean ₹26.20 Cr. PBT itself fell a sharper 26.0% YoY; a lower effective tax rate (18.9% vs 25.8% a year ago) cushioned the PAT decline to 19.2%. Standalone PAT fell steeper, -31.3% YoY to ₹19.12 Cr, versus consolidated's smaller -19.2% YoY decline — a divergence of over 10 points, meaning the overseas subsidiaries held up better than the parent this quarter. Segment-wise, revenue growth was led by India (+6.5% YoY to ₹130.5 Cr) and Middle East (+6.6% YoY to ₹28.2 Cr), the latter consistent with management's stated focus on high-margin Middle East/Southeast Asia deals from the Q1 call — though that growth has not yet shown up in consolidated margins. Separately, the company disclosed a ₹17.49 Cr GST show-cause notice on September 29, 2026, a contingent liability not reflected in this quarter's nil exceptional-items line. Going into Q3 FY27, the trend to watch is whether the employee-cost ratio keeps easing from Q1's 74.7% toward last year's sub-70% base, and whether the order book management flagged on the Q1 call (₹1,244 Cr, up from ₹1,044 Cr) starts converting into margin recovery rather than just topline growth.

31 Oct 2026, 04:10 pm

Corporate Events

Board MeetingNUCLEUS
2026
31Oct

Board Meeting

The Board of Directors meeting is scheduled to consider and …

BSE Filing ↗
Board MeetingNUCLEUS
2026
30Jul

Board Meeting

The Board of Directors meeting is scheduled to consider and …

BSE Filing ↗
Board MeetingNUCLEUS
2026
27Jul

Board Meeting

The Thirty-Seventh (37th) Annual General Meeting of Nucleus …

BSE Filing ↗
DividendNUCLEUS
2026
10Jul

₹12.5 / share

BSE Filing ↗
Board MeetingNUCLEUS
2026
21May

Board Meeting

The Board of Directors had recommended a final dividend for …

BSE Filing ↗
Board MeetingNUCLEUS
2026
10Feb

Board Meeting

Approval and Adoption of the Audited Standalone Financial re…

BSE Filing ↗
Board MeetingNUCLEUS
2025
31Jul

Board Meeting

Approval and Adoption of the Audited Standalone Financial re…

BSE Filing ↗
DividendNUCLEUS
2025
11Jul

₹12.5 / share

BSE Filing ↗
Board MeetingNUCLEUS
2025
16May

Board Meeting

For Approval and Adoption of the Audited Standalone Financia…

BSE Filing ↗
Board MeetingNUCLEUS
2025
28Jan

Board Meeting

Approval and Adoption of Audited Standalone Financial result…

BSE Filing ↗
Board MeetingNUCLEUS
2024
12Nov

Board Meeting

Approval and Adoption of Audited Standalone Financial result…

BSE Filing ↗
Board MeetingNUCLEUS
2024
22Aug

Board Meeting

BuyBack Of Equity Shares Of The Company

BSE Filing ↗
Board MeetingNUCLEUS
2024
3Aug

Board Meeting

Approval and Adoption of Audited Standalone Financial result…

BSE Filing ↗
Board MeetingNUCLEUS
2024
23May

Board Meeting

For Approval and Adoption of the Audited Standalone and Cons…

BSE Filing ↗
Board MeetingNUCLEUS
2024
12Feb

Board Meeting

Approval and Adoption of Audited Standalone Financial result…

BSE Filing ↗
Board MeetingNUCLEUS
2023
9Nov

Board Meeting

Approval and Adoption of Audited Standalone Financial result…

BSE Filing ↗